MARKET

INTS

INTS

INTENSITY THERAPEUTICS INC
NASDAQ
4.920
+0.140
+2.93%
After Hours: 4.910 -0.01 -0.20% 16:41 07/13 EDT
OPEN
4.845
PREV CLOSE
4.780
HIGH
4.950
LOW
4.801
VOLUME
46.23K
TURNOVER
--
52 WEEK HIGH
43.50
52 WEEK LOW
3.510
MARKET CAP
13.30M
P/E (TTM)
-0.6850
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INTS last week (0706-0710)?
Weekly Report · 14h ago
Weekly Report: what happened at INTS last week (0629-0703)?
Weekly Report · 07/06 09:02
Intensity Therapeutics targets strategic partnerships to accelerate INT230-6 development
PUBT · 07/01 12:07
Intensity Therapeutics resumes enrollment in Phase 3 INT230-6 soft tissue sarcoma trial
PUBT · 07/01 12:04
INTENSITY THERAPEUTICS - OVER 200 PATIENTS ENROLLED IN COMPLETED INT230-6 STUDIES WITH PEER-REVIEWED PUBLICATION
Reuters · 07/01 12:00
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
PR Newswire · 07/01 12:00
Weekly Report: what happened at INTS last week (0622-0626)?
Weekly Report · 06/29 09:02
Weekly Report: what happened at INTS last week (0615-0619)?
Weekly Report · 06/22 09:02
More
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Webull offers Intensity Therapeutics Inc stock information, including NASDAQ: INTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INTS stock methods without spending real money on the virtual paper trading platform.